Prospera Insights
Back to queue

Tata India Pharma & Healthcare Fund

Tata Mutual Fund · 135810 · Quant Rank #338

Structural GatesFully Researched (Deep)Prospera Research Confidence: HIGH
ANALYST_REVIEWED

Research Confidence reflects source quality and evidence depth — it is independent of the score below. A fund can score highly with low confidence, or moderately with high confidence.

Real Evidence
CategoryPH
AUM₹1,541 Cr
Benchmark—
RiskometerVery High
TER0.63%
InceptionInsufficient data
Track RecordInsufficient data
Fund ManagerRajat Srivastava
AUM Floor₹300 Cr
Min Track3 yrs
Max Alloc12%
Returns vs Benchmark
WindowFundBenchmark
Calculated Parameters
FMT7/10
AMQ5/10
AUTInsufficient data — no real 3-months-ago AUM evidence (AMFI's live feed only carries current + ~1-month-ago; needs a genuine dated snapshot from an earlier sync)
ERS7/10
Structural Gates
Gate 1 — EligibilityUNKNOWN

AUM floor: PASS · Track record: UNKNOWN · SEBI: UNKNOWN

Gate 2 — Quant ScreenFAIL
Gate 3 — Top 10FAIL
Gate 4 — Top 5FAIL
Gate 5 — Top 2 ICFAIL
Candidate's 42.8 would rank #3 among 2 real existing category scores (top 2 = recommendable).
Analyst Name
MOM — Momentum
7% weight
Deep Research

3–6M price+flow vs benchmark · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

CON — Consistency
10% weight
Deep ResearchConfidence: HIGH

3Y/5Y quartile rank stability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

PQT — Portfolio Quality
11% weight
Deep ResearchConfidence: MEDIUM

PE, concentration, churn · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

FMQ — Fund Mgr Quality
12% weight
Deep ResearchConfidence: HIGH

Philosophy, communication, style drift · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

VAL — Valuation Risk
10% weight
Deep Research

Portfolio PE/PB vs category avg · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

STW — Sector Tailwinds
9% weight
Deep ResearchConfidence: MEDIUM

Policy/macro drivers 12-18M · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

DSP — Downside Protection
8% weight
Deep Research

Max DD, Sortino, bear markets · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

OPP — Outperformance Prob.
8% weight
Deep ResearchConfidence: MEDIUM

Analyst 12M alpha probability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

THS — Thesis Strength
2% weight
Deep ResearchConfidence: MEDIUM

Analyst 12-24M thesis conviction · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:27 AM

V6 Final Score
42.8
/ 100 — Final Score
AVOID
MOM
0.0
CON
6.0
PQT
6.6
FMQ
8.4
VAL
0.0
STW
5.4
DSP
0.0
OPP
4.0
FMT
5.6
AMQ
3.0
AUT
—
ERS
2.8
THS
1.0
Data-limited: AUT (insufficient data — never defaulted to 0)
Source Evidence (8)
Fund ManagerRajat Srivastava
Value Research Online — public fund page as of 2026-08-27
Fund Manager - Managing SinceDecember 28, 2015
Value Research Online — public fund page as of 2026-08-27
Value Research Rating3 out of 5 stars
Value Research Online — public fund page as of 2026-08-27
Top 5 HoldingsSun Pharmaceutical 8.59%, Divi's Lab 6.36%, Healthcare Global 5.85%, Abbott India 5.63%, Rainbow Children's 4.90% (top-5 total 31.33%)
Value Research Online — public fund page as of 2026-08-27
AUM (Cr.)1541
Value Research Online — public fund page as of 2026-08-27
Total Expense Ratio - Direct Plan (%)0.63
Value Research Online — public fund page as of 2026-08-27
Riskometer (Scheme)Very High
Value Research Online — public fund page as of 2026-08-27
AMC Total AUM (Lakh Cr.)2.29
AMFI quarterly AAUM disclosure (Apr–Jun 2026), via RightAdvise aggregation of official AMFI figures as of 2026-06-30
Audit Log
MOM ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] No real return-vs-benchmark figure collected specifically for this scheme (a real absolute 5Y CAGR of 15.46% was found, but not benchmark-relative). Scored 0 (N/A) rather than guessed.”
CON ∅ → 6 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] Real Value Research rating is 3 out of 5 stars, confirmed directly on the fund's own VR page. Approved substitution: 3★ = 6.”
PQT ∅ → 6 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] Real top-5 holdings: Sun Pharmaceutical 8.59%, Divi's Lab 6.36%, Healthcare Global 5.85%, Abbott India 5.63%, Rainbow Children's 4.90% (top-5 total 31.33%) — genuinely diversified across pharma manufacturing, hospitals (Healthcare Global, Rainbow Children's), and MNC pharma (Abbott).”
FMQ ∅ → 7 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] Real manager: Rajat Srivastava, managing since December 28, 2015 — a genuine, real, long tenure (~11 years) on this specific scheme, among the longest verified in this pass.”
VAL ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] No PE/PB evidence found. Scored 0 (N/A).”
STW ∅ → 6 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] Real, current sector-level tailwind in Indian pharma/healthcare; portfolio genuinely diversified across manufacturing and hospital-services sub-themes.”
DSP ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] No real drawdown/Sortino evidence found. Scored 0 (N/A).”
OPP ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH — analyst judgment] A genuinely long-tenured manager and a real 3-star rating are real positives; Value Research's own published view on this fund states 'most investors can skip these funds and stick to diversified equity funds instead' — a real, disclosed caution this pass takes seriously, scoring at a moderate rather than high level.”
THS ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:27 AM
“[DEEP RESEARCH] Long-running, genuinely diversified pharma-sector thesis under an 11-year-tenured manager, tempered by Value Research's own real, disclosed skip recommendation for narrow-mandate sector funds generally.”